{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T15:36:55Z","timestamp":1712331415087},"reference-count":10,"publisher":"Georg Thieme Verlag KG","issue":"06","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Gastroenterol"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die antivirale Erstlinientherapie mit direkt antiviral wirkenden Medikamenten (DAA) bei Patienten mit chronischer Hepatitis-C-Virus-Infektion (HCV) f\u00fchrt in &gt;90% der F\u00e4lle zu einer Ausheilung der Erkrankung. Selbst nach Versagen der Erstlinientherapie gibt es eine etablierte und gut wirksame Behandlungsoption mit Sofosbuvir + Velpatasvir + Voxilaprevir (SOF\/VEL\/VOX). Allerdings gibt es einige Patienten, die selbst nach einer zweiten antiviralen Therapie keine Ausheilung erreichen. Oftmals gibt es Faktoren wie das Vorliegen einer Leberzirrhose oder einer Virusvariante, die mit einem Therapieversagen assoziiert sind. Zurzeit empfehlen europ\u00e4ische und amerikanische Leitlinien den Einsatz von SOF in Kombination mit Glecaprevir\/Pibrentasvir (G\/P) + Ribavirin (RBV) als Reservetherapie. Jedoch gibt es derzeit nur unzureichende Evidenz, um die Wirksamkeit bei diesen schwer zu behandelnden Patienten zu best\u00e4tigen. Im Folgenden wird \u00fcber 2 Patienten mit HCV-Infektion (Genotyp 3 mit Y93H-Variante) und Leberzirrhose berichtet, bei denen mit einer Kombination von SOF + G\/P \u00b1 RBV eine dauerhafte HCV-Ausheilung erzielt werden konnte. Bei einem Patienten lag zum Zeitpunkt des Therapiestarts bereits eine Child-B-Zirrhose vor, es kam zu keinerlei schweren Nebenwirkungen. Diese Daten unterst\u00fctzen also einen Einsatz von SOF + G\/P \u00b1 RBV bei Patienten mit Re-Therapieversagen nach SOF\/VEL\/VOX-Therapie.<\/jats:p>","DOI":"10.1055\/a-1649-8931","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T23:49:37Z","timestamp":1634687377000},"page":"959-962","source":"Crossref","is-referenced-by-count":4,"title":["Glecaprevir\/Pibrentasvir + Sofosbuvir + Ribavirin als Reserveregime nach Sofosbuvir + Velpatasvir + Voxilaprevir Re-Therapieversagen"],"prefix":"10.1055","volume":"60","author":[{"given":"Tammo L.","family":"Tergast","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaus","family":"Kordecki","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie und Diabetologie, Bonifatius Hospital Lingen, Lingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie","family":"Ohlendorf","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Beier","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Sandmann","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heiner","family":"Wedemeyer","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Cornberg","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Maasoumy","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Deutschland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2021,10,19]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.1056\/NEJMoa1613512","article-title":"Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection","volume":"376","author":"M Bourli\u00e8re","year":"2017","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Hepatitis C guidance 2019 update: American Association for the Study of Liver Diseases\u2013Infectious Diseases Society of America recommendations for testing, managing, and treating hepatitis C virus infection","volume":"71","author":"MG Ghany","year":"2020","journal-title":"Hepatology"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.jhep.2019.01.031","article-title":"Retreatment of patients who failed glecaprevir\/pibrentasvir treatment for hepatitis C virus infection","volume":"70","author":"D Wyles","year":"2019","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.05.029","article-title":"Efficacy of NS5A inhibitors against unusual and potentially difficult-to-treat HCV subtypes commonly found in sub Saharan Africa and South East Asia","author":"D Nguyen","year":"2020","journal-title":"J Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.02.024","article-title":"Glecaprevir\/pibrentasvir sofosbuvir ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings","author":"MT Martin","year":"2021","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2021.02.024","article-title":"Glecaprevir\/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings","volume":"75","author":"MT Martin","year":"2021","journal-title":"J Hepatol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2111","DOI":"10.1053\/j.gastro.2018.03.022","article-title":"Baseline factors associated with improvements in decompensated cirrhosis after direct-acting antiviral therapy for hepatitis C virus infection","volume":"154","author":"O El-Sherif","year":"2018","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: A European study","volume":"65","author":"LS Belli","year":"2016","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1053\/j.gastro.2018.06.042","article-title":"Efficacy of sofosbuvir and velpatasvir, with and without ribavirin, in patients with hepatitis C virus genotype 3 infection and cirrhosis","volume":"155","author":"R Esteban","year":"2018","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: importance of resistance","author":"C Sarrazin","year":"2021","journal-title":"J Hepatol"}],"container-title":["Zeitschrift f\u00fcr Gastroenterologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1649-8931.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:18:07Z","timestamp":1654647487000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1649-8931"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,19]]},"references-count":10,"journal-issue":{"issue":"06","published-online":{"date-parts":[[2022,6,7]]},"published-print":{"date-parts":[[2022,6]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1649-8931","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0044-2771","1439-7803"],"issn-type":[{"value":"0044-2771","type":"print"},{"value":"1439-7803","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,19]]}}}